Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα mRNA and improvement in disease activity scores In an acute...
United States Jody Cain Jeromed Jabbour Matinas Biopharma James Ferguson Matinas Biopharma Holdings Inc
Source: marketscreener.com